February 4, 2021Open Access
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Key Points
Key points are not available for this paper at this time.
Abstract
This analysis confirms the IDFS benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early BC. Longer follow-up is needed to fully assess OS benefit.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Martine Piccart
Université Libre de Bruxelles
M
Marion Procter
Frontier Agriculture (United Kingdom)
D
Debora Fumagalli
European Institute of Oncology
Journals
Journal of Clinical Oncology
Actions
Institutions
Harvard University
Dana-Farber Cancer Institute
The University of Texas MD Anderson Cancer Center
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...